IOVANCE BIOTHERAPEUTICS, INC. Annual Deferred Income Tax Expense (Benefit) in USD for 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Iovance Biotherapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate for 2023.
  • Iovance Biotherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$1.41M.
Deferred Income Tax Expense (Benefit), Annual (USD)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$3.48M Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.